Sandoz lowers Glatopa (glatiramer acetate injection) price in US to offer people with MS high-quality care at a more affordable price

Sandoz Inc. (Sandoz), a Novartis company, today announced it has lowered the wholesale acquisition cost (WAC) of Glatopa® (glatiramer acetate injection) 20 mg/mL and Glatopa 40 mg/mL in the US, to be part of the solution by offering people living with multiple sclerosis (MS) high-quality care at a more affordable price.

MS is a chronic disorder of the central nervous system that affects around 400,000 people in the US1. In addition to the personal burden of MS for patients and families, affordability is a significant challenge for MS medicines globally. A recent report highlighted affordability as the most common challenge affecting access to MS therapy in 46% of the 90 countries included2.

Both doses of Glatopa now have the lowest WAC of all glatiramer acetate injection medicines available to people living with MS in the US at $1,500 for a one-month supply. This is approximately 79% and 74% lower than Teva’s Copaxone®* 20 mg/mL ($7,114 WAC for a one-month supply) and 40 mg/mL doses ($5,832 WAC for a one-month supply), respectively, and approximately 23% lower than Mylan’s glatiramer acetate injection 20 mg/mL and 40 mg/mL doses ($1,950 WAC for a one-month supply)3.

“We believe that the strong relationships and trust we have built with healthcare professionals since launching Glatopa in 2015 are another key differentiator for us – built on real world experience and our reputation for delivering high quality medicines,” said Joanne Manidis, Executive Director of Specialty Products at Sandoz Inc. “By choosing a Sandoz medicine, healthcare professionals will be part of the solution in offering people living with MS high-quality care at a more affordable price, creating a more sustainable system for patients now and in the future.”

The Sandoz GlatopaCare service will remain with a $0 Co-Pay Program for eligible patients. To help increase patient confidence with administering injections, patients receive personalized injection training, 24-hour access to nurses for Glatopa-related questions and a free Starter Kit, which includes the Glatopaject® injection device, designed to work with both Glatopa 20 mg/mL and 40 mg/mL prefilled syringes. To learn more, visit glatopa.com/glatopa-care/what-is-glatopacare or call 1-855-GLATOPA.

Glatopa® Indication and Important Safety Information

Indication

Glatopa® is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

Important Safety Information

Do not take Glatopa® if you are allergic to glatiramer acetate, mannitol, or any of the ingredients in Glatopa.

Some patients report a short-term reaction right after or within minutes after injecting glatiramer acetate. This reaction can involve flushing (feeling of warmth and/or redness), chest tightness or pain, fast heartbeat, anxiety, and trouble breathing. These symptoms generally appear within seconds to minutes of an injection, last about 15 minutes, and do not require specific treatment. During the postmarketing period, there have been reports of patients with similar symptoms who received emergency medical care. If symptoms become severe, call the emergency phone number in your area. Call your doctor right away if you develop hives, skin rash with irritation, dizziness, sweating, chest pain, trouble breathing, or severe pain at the injection site. If any of the above occurs, do not give yourself any more injections until your doctor tells you to begin again.

Chest pain may occur either as part of the immediate post-injection reaction or on its own. This pain should only last a few minutes. You may experience more than one such episode, usually beginning at least one month after starting treatment. Tell your doctor if you experience chest pain that lasts for a long time or feels very intense.

A permanent indentation under the skin (lipoatrophy) or, rarely, necrosis at the injection site may occur, due to local destruction of fat tissue. Be sure to follow proper injection technique and inform your doctor of any skin changes.

The most common side effects in studies of glatiramer acetate injection are redness, pain, swelling, itching, or a lump at the site of injection, flushing, rash, shortness of breath, and chest pain. These are not all of the possible side effects of glatiramer acetate. For a complete list, ask your doctor or pharmacist. Tell your doctor about any side effects you have while taking Glatopa.

To report SUSPECTED ADVERSE REACTIONS, contact Sandoz Inc. at 1-800-525-8747 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information for Glatopa.

*Copaxone is a registered trademark of Teva Pharmaceutical Industries Ltd.

# # #

References

  1. Tullman M. Overview of the epidemiology, diagnosis and disease progression associated with multiple sclerosis. Am J Managed Care. 2013 Feb;19(2 Suppl):S15-20.
  2. Multiple Sclerosis International Federation. The atlas of MS international report. Available at: http://www.msif.org/wp-content/uploads/2014/09/Atlas-of-MS.pdf. Accessed September 23, 2019.
  3. AnalySource data as of September 27, 2019.

For further information, contact:

Sandoz US Communications

Leslie Pott

+1 609 627 5287

leslie.pott@sandoz.com

To read more Press Release articles, click here.